Nanexa (NANEXA) Q3 2025 earnings summary

Executive summary

• Extended a feasibility agreement with a major pharmaceutical company for PharmaShell platform use in a drug with annual sales over $1 billion.

• Granted a key patent in Japan for PharmaShell technology; three new patent applications filed in strategic countries.

• Presented first-in-kind Phase I proof-of-concept data for NEX-22, a once-monthly GLP-1 therapy for type 2 diabetes.

• Continued business development, focusing on licensing assets in type 2 diabetes and obesity, with strong market interest.

• Selected as a finalist in the Drug Delivery Technology category by Fierce Life Sciences.

Financial highlights

• Q3 turnover: SEK 477 thousand (vs. SEK 6,434 thousand in Q3 2024); 9M turnover: SEK 6,059 thousand (vs. SEK 19,844 thousand in 9M 2024).

• Q3 EBIT: SEK -11,983 thousand (vs. SEK -4,550 thousand); 9M EBIT: SEK -25,433 thousand (vs. SEK -14,037 thousand).

• Q3 net loss: SEK -12,538 thousand (vs. SEK -4,438 thousand); 9M net loss: SEK -27,424 thousand (vs. SEK -13,273 thousand).

• Q3 EPS: SEK -0.08 (vs. SEK -0.03); 9M EPS: SEK -0.18 (vs. SEK -0.10).

• Cash and cash equivalents at period end: SEK 24,779 thousand (vs. SEK 29,009 thousand in 2024).

Outlook and guidance

• Board believes current working capital and cash are sufficient to finance operations until end of Q1 2026.

• Ongoing business development and licensing discussions expected to secure continued funding.